Capmatinib (INCB-28060, INC-280) is a highly potent, selective, ATP competitive inhibitor of c-MET kinase with IC50 of 0.13 nM.
Capmatinib (INCB-28060, INC-280) displays no activity against RONβ, EGFR and HER-3.
Capmatinib (INCB-28060, INC-280) inhibits c-MET phosphorylation (IC50=1 nM) in SNU-5 human gastric cancer cell line, is slightly more potent in H596 and H1437 lung cancer cell lines that express mutant c-MET due to an exon 14 deletion and a R988C mutation.
Capmatinib (INCB-28060, INC-280) inhibits c-MET phosphorylation and tumor growth in c-MET-driven mouse tumor models.
